Get the Stockscreener App
6.07
4.66%
0.27
After Hours:
6.07
Karyopharm Therapeutics Inc stock is traded at $6.07, with a volume of 198.18K.
It is up +4.66% in the last 24 hours and down -4.86% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$5.80
Open:
$5.8
24h Volume:
198.18K
Relative Volume:
0.99
Market Cap:
$52.63M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.551
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
-5.45%
1M Performance:
-4.86%
6M Performance:
-17.53%
1Y Performance:
-55.20%
1-Day Range:
$5.6585
$6.17
1-Week Range:
$5.6585
$6.60
52-Week Range:
$3.51
$14.24
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.07 | 92.38M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Karyopharm (KPTI) Reports Strong Q3 2025, Highlights Myelofibros - GuruFocus
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025 - MarketScreener
Transcript : Karyopharm Therapeutics Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Karyopharm Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Karyopharm Therapeutics: Q3 Earnings Snapshot - CTPost
Karyopharm Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Karyopharm Q3 2025 shows revenue growth, pre-market dip - Investing.com
How geopolitical tensions affect Karyopharm Therapeutics Inc. stock2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Karyopharm Grows Revenue With Strong XPOVIO Sales And Partnerships - Finimize
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Analyzing net buyer seller activity in Karyopharm Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - newser.com
Karyopharm (KPTI) Surpasses Q3 Revenue Expectations with Clinica - GuruFocus
Karyopharm (KPTI) Projects Revenue Growth and Expense Reduction for FY25 - GuruFocus
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics' Q3 net loss widens - TradingView
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PR Newswire
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsQuarterly Market Review & Verified Technical Trade Signals - newser.com
Quantitative breakdown of Karyopharm Therapeutics Inc. recent moveWeekly Trade Recap & Daily Risk Controlled Trade Plans - newser.com
Karyopharm Therapeutics Inc. stock trend outlook and recovery path2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Is it time to cut losses on Karyopharm Therapeutics Inc.July 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Using Ichimoku Cloud for Karyopharm Therapeutics Inc. technicalsQuarterly Earnings Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock cheap vs fundamentalsMarket Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Will Karyopharm Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Can Karyopharm Therapeutics Inc. stock continue upward trend2025 Market Sentiment & Daily Stock Trend Reports - newser.com
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investors2025 Technical Overview & Reliable Volume Spike Alerts - newser.com
Is Karyopharm Therapeutics Inc. stock safe for conservative investorsPortfolio Profit Report & AI Based Buy/Sell Signal Reports - newser.com
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risksWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Karyopharm Therapeutics Inc expected to post a loss of $3.13 a shareEarnings Preview - TradingView
Earnings To Watch: Karyopharm Therapeutics Inc (KPTI) Reports Q3 2025 Result - Yahoo Finance
Technical signs of recovery in Karyopharm Therapeutics Inc.2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Regression analysis insights on Karyopharm Therapeutics Inc. performance2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-31 05:27:00 - newser.com
Can Karyopharm Therapeutics Inc. (25K0) stock sustain revenue momentumQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Karyopharm Therapeutics (KPTI) Price Target Decreased by 10.98% to 15.98 - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):